Dynamic Technology Lab Private Ltd Takes $605,000 Position in RxSight, Inc. (NASDAQ:RXST)

Dynamic Technology Lab Private Ltd acquired a new position in RxSight, Inc. (NASDAQ:RXST - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 12,232 shares of the company's stock, valued at approximately $605,000.

Several other institutional investors also recently modified their holdings of the business. Larson Financial Group LLC boosted its position in RxSight by 55.8% during the third quarter. Larson Financial Group LLC now owns 1,536 shares of the company's stock valued at $76,000 after acquiring an additional 550 shares during the last quarter. Algert Global LLC boosted its position in RxSight by 55.1% during the third quarter. Algert Global LLC now owns 64,148 shares of the company's stock valued at $3,171,000 after acquiring an additional 22,792 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in RxSight by 28.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 285,329 shares of the company's stock valued at $14,104,000 after acquiring an additional 62,507 shares during the last quarter. Brown Capital Management LLC bought a new stake in RxSight during the third quarter valued at $26,813,000. Finally, Intech Investment Management LLC bought a new stake in RxSight during the third quarter valued at $598,000. Institutional investors own 78.78% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on RXST. Stifel Nicolaus cut their price target on shares of RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. Wells Fargo & Company cut their price objective on shares of RxSight from $68.00 to $54.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th. Jefferies Financial Group began coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a "buy" rating and a $72.00 price objective on the stock. Needham & Company LLC reissued a "buy" rating and set a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Finally, Oppenheimer cut their price objective on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $61.63.

RxSight Trading Up 1.0 %

Shares of RXST traded up $0.48 on Friday, reaching $46.88. The company's stock had a trading volume of 254,146 shares, compared to its average volume of 486,556. RxSight, Inc. has a twelve month low of $28.88 and a twelve month high of $66.54. The stock has a market capitalization of $1.89 billion, a PE ratio of -56.48 and a beta of 1.19. The firm has a fifty day moving average of $48.70 and a 200-day moving average of $52.39.

Insider Buying and Selling

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $45.00, for a total value of $139,500.00. Following the completion of the sale, the insider now owns 42,246 shares in the company, valued at approximately $1,901,070. This trade represents a 6.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jesse Anderson Corley bought 11,111 shares of the company's stock in a transaction on Tuesday, November 12th. The shares were purchased at an average cost of $45.37 per share, for a total transaction of $504,106.07. Following the transaction, the director now owns 468,571 shares in the company, valued at approximately $21,259,066.27. This represents a 2.43 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 62,702 shares of company stock worth $3,059,197 in the last quarter. Insiders own 9.36% of the company's stock.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.